BTL Vanquish Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has approved the BTL Vanquish for circumferential reduction of the abdomenal area. The platform features a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application (without touching patients’ skin). It creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue. “FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” says Andrea Morrison, BTL director of clinical development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”

Suggested Articles

AAFPRS announced that Mary Lynn Moran, M.D. will serve as president of the organization for the 2019-2020 year term.

Dermatologists are the leading influencers for cosmetic procedures and skincare choices.

Unrealistic expectations of self-image driven by social media lead to disappointed clients.